YouTube video by Dr. Rob Swanda

YouTube video by Dr. Rob Swanda

New clinical results from Johnson & Johnson reveal the investigational combination of bispecific antibodies TALVEY and TECVAYLI demonstrates a high response rate in aggressive multiple myeloma patients.

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma […]

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

'Talvey' es un anticuerpo biespecífico que logra prolongar la supervivencia en cuarta línea de tratamiento. Puede usarse antes y después de la terapia anti-BCMA.

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

'Combinations represent additional options for early-line treatment,' researcher says

Learn how Talvey plus Tecvayli cut the risk of myeloma progression or death by 89%, how the combination is given and what it may mean for daily life.

Johnson & Johnson has reported promising results for TECVAYLI® and TALVEY®, demonstrating an 89% reduction in disease progression risk in myeloma patients.

Johnson & Johnson (NYSE: JNJ) reported positive topline results from the Phase 3 MonumenTAL-6 trial in adults with relapsed or refractory multiple myeloma after 1–4 prior therapies, including an anti-CD38 antibody and lenalidomide. The study compared TECVAYLI + TALVEY (Tec-Tal) and TALVEY + pomalidomide (Tal-P) against investigator’s choice of EPd or PVd standard regimens.According to Johnson & Johnson, Tec-Tal reduced the risk of disease progression or death by 89% (HR 0.11; 95% CI 0.08–0.16; p<0.0001) and the risk of death by 62% (HR 0.38) versus standard of care, with Tal-P reducing progression or death risk by 73% (HR 0.27; 95% CI 0.2–0.35). Both investigational arms met the primary endpoint of progression-free survival, and safety was described as consistent with the known profiles of each monotherapy. An Independent Data Monitoring Committee recommended unblinding at the first interim analysis, and full data will be presented at a future medical meeting and shared with regulators.

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further...

Buy Talquetamab (Talvey) injection online in India at a genuine price. Call +91 9967979080 for latest cost, access support & safe delivery.

Johnson & Johnson announced on June 15 new results from the phase II RedirecTT-1 study evaluating the investigational combination of Talvey (talquetamab-tgvs), the first U.S. FDA-approved GPRC5D-directed bispecific antibody, and Tecvayli (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific antibody. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

 Geachte voorzitter, Het kabinet stelt de Kamer hierbij op de hoogte van de prijsonderhandelingen voor de sluisgeneesmiddelen Tecvayli (teclistamab) en Talvey (talquetamab). Deze zogenaamde bispecifieke antilichamen worden gebruikt bij de behandeling van volwassen patiënten met multipel myeloom (de ziekte van Kahler) die al drie eerdere behandelingen gehad hebben en bij wie de ziekte is teruggekomen. Zorginstituut Nederland (hierna: Zorginstituut) heeft eerder geadviseerd om deze geneesmiddelen, na succesvolle prijsonderhandelingen, te vergoeden1,2. Ondanks intensieve pogingen om afspraken t…

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma

New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and Tecvayli for RRMM.

New research reveals the effectiveness of the TALVEY® and DARZALEX FASPRO® combo, achieving significant survival rates in multiple myeloma patients. Find out more about this groundbreaking treatment.